Canine Atopic Dermatitis

Global Canine Atopic Dermatitis Market to Reach US$2.5 Billion by 2030

The global market for Canine Atopic Dermatitis estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Glucocorticoids, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Antihistamines segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$408.6 Million While China is Forecast to Grow at 12.1% CAGR

The Canine Atopic Dermatitis market in the U.S. is estimated at US$408.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$636.3 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Canine Atopic Dermatitis Market – Key Trends & Drivers Summarized

Why Is Canine Atopic Dermatitis Gaining Attention in Veterinary Healthcare?

Canine atopic dermatitis (CAD) is one of the most common skin disorders affecting dogs, characterized by chronic inflammation and itching caused by environmental allergens such as pollen, dust mites, and molds. The condition is gaining significant attention in veterinary healthcare due to its increasing prevalence and its impact on dogs’ quality of life. Canine atopic dermatitis often leads to persistent itching, scratching, and skin infections, which can cause significant discomfort and require long-term management. Veterinary experts estimate that 10% to 15% of dogs globally suffer from some form of atopic dermatitis, with certain breeds like Golden Retrievers, Bulldogs, and German Shepherds being particularly prone to the condition. Pet owners are becoming more aware of canine skin health, and there is a growing demand for effective treatments that address both the symptoms and the underlying causes of CAD. The veterinary healthcare industry has responded by developing a range of therapies, including corticosteroids, antihistamines, immune-modulating drugs, and specialized diets designed to reduce allergic reactions. As pet ownership rises, particularly in developed countries where pets are considered part of the family, more resources are being devoted to the diagnosis, treatment, and management of chronic conditions like CAD.

How Are Innovations in Diagnosis and Treatment Improving Canine Atopic Dermatitis Care?

Advancements in diagnostic tools and treatments are revolutionizing the management of canine atopic dermatitis. Veterinarians are now using more precise diagnostic methods, such as intradermal skin testing and allergen-specific immunotherapy (ASIT), to identify the specific allergens triggering a dog`s symptoms. These diagnostic techniques allow for more targeted and personalized treatments, which can significantly improve outcomes. In particular, ASIT involves desensitizing dogs to the allergens they are allergic to, reducing their allergic reactions over time. This form of treatment is particularly beneficial for dogs that do not respond well to conventional therapies or have severe, recurring symptoms. On the treatment front, there have been notable advancements in the development of biologic therapies and immunomodulators. Cytopoint, for instance, is a monoclonal antibody that targets interleukin-31 (IL-31), a key protein involved in the itch signal, and has gained popularity for its ability to provide long-lasting relief from itching with fewer side effects compared to traditional corticosteroids. Similarly, Apoquel, an immune-modulating drug, has been widely adopted for its effectiveness in reducing inflammation and itchiness in dogs with atopic dermatitis. These treatments, which offer more targeted approaches with fewer side effects, represent significant progress in managing a condition that often requires lifelong therapy.

How Are Changing Consumer Behaviors Shaping the Canine Atopic Dermatitis Market?

As pet ownership trends evolve, consumer behaviors are increasingly influencing the canine atopic dermatitis market. Pet owners today are more invested in their pets` health and well-being, often seeking premium healthcare solutions and proactive treatments. This growing trend of "humanization" of pets is driving demand for advanced and innovative therapies that not only alleviate symptoms but also improve the overall quality of life for pets. As a result, veterinary healthcare providers are witnessing a rising demand for personalized treatments, allergen-free diets, and even alternative therapies such as acupuncture and herbal treatments to manage canine atopic dermatitis.

Another key factor shaping the market is the increased use of telemedicine and digital health platforms in veterinary care. Pet owners are turning to online platforms to consult with veterinary dermatologists and access information on how to better manage chronic conditions like CAD. This shift toward digital healthcare services is making it easier for pet owners to receive timely advice and access specialized care that may not be readily available locally. Moreover, the demand for natural and organic pet products is influencing the development of hypoallergenic pet foods and topical treatments, which cater to owners seeking gentler, non-pharmaceutical approaches to managing their dogs’ skin conditions.

Growth in the Canine Atopic Dermatitis Market Is Driven by Several Factors

Growth in the canine atopic dermatitis market is driven by several factors, including advancements in veterinary healthcare, the rising awareness among pet owners, and the increasing demand for innovative treatments. Technological progress in diagnostics, particularly in identifying specific allergens through skin testing and serum-based tests, has enabled veterinarians to offer more targeted and effective treatments for dogs with atopic dermatitis. The introduction of biologic therapies, like monoclonal antibodies and immune modulators, has provided pet owners with more options for long-term management of the condition, reducing the need for steroids and other drugs that can have severe side effects when used over extended periods. Another key growth driver is the rising number of pet owners who are more invested in ensuring their pets receive high-quality healthcare. This demographic shift, particularly in developed regions, has led to increased spending on veterinary services and medications, including those related to skin conditions like CAD. The growing interest in hypoallergenic diets and allergen-free pet products is also boosting the market for dietary interventions and topical treatments aimed at controlling flare-ups. Additionally, the integration of telemedicine in veterinary care is making it easier for pet owners to manage chronic conditions like CAD, with online consultations offering guidance on treatment plans and symptom management. These factors, along with the increasing focus on pet wellness and preventative care, are expected to continue driving the expansion of the canine atopic dermatitis market.

SCOPE OF STUDY:

The report analyzes the Canine Atopic Dermatitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Other Products); Mode of Administration (Oral, Injectable, Topical)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Aclaris Therapeutics
• Bioiberica SAU
• Boehringer Ingelheim International GmbH
• Botanix Pharmaceuticals
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Johnson & Johnson Services, Inc.
• KH Neochem Co., Ltd.
• Nippon Zenyaku Kogyo Co., Ltd.
• Pfizer, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.